Genfit is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory and metabolic diseases of the liver. The company’s lead program targets nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) through selective modulation of peroxisome proliferator-activated receptors (PPARs). In addition to its small-molecule pipeline, Genfit is advancing proprietary diagnostic tools designed to improve disease staging and patient stratification, underscoring its integrated approach to drug development and precision medicine.
The company’s most advanced asset, elafibranor, is a dual PPAR‐α/δ agonist that has undergone extensive clinical evaluation for NASH. Genfit’s research portfolio also includes pipelines for fibrosis and cholestatic liver diseases, as well as companion diagnostics such as the NIS4 panel, which measures gene expression markers to aid in noninvasive assessment of NASH severity. By combining therapeutic and diagnostic modalities, Genfit aims to address unmet needs in chronic liver disease and streamline clinical trial design.
Founded in 1999 as a spin-off from the University of Lille, Genfit has established a presence in Europe and North America, with corporate headquarters in Lille, France, and a research office in Cambridge, Massachusetts. Over the years, the company has fostered collaborations with academic institutions, patient advocacy groups and pharmaceutical partners to advance its clinical and diagnostic programs. Genfit’s global footprint enables it to conduct multicenter trials and access diverse patient populations.
Led by Chief Executive Officer Pascal Prigent, Genfit benefits from a management team with deep expertise in hepatology, regulatory affairs and commercial development. The company’s governance structure and strategic partnerships support its mission to bring first-in-class and best-in-class treatments to patients with serious liver conditions. As Genfit progresses through late-stage clinical milestones, it remains committed to leveraging scientific innovation and diagnostic precision to transform liver disease care.
AI Generated. May Contain Errors.
Free GNFT Stock Alerts